Revelation Biosciences, Inc. (REVB) Stock Forecast
REVB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $17.75 average of analyst targets
- Upside to target
- +3,559.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.88
- 52-week range
- $0.48 – $8.80
REVB analyst ratings
1 analystsNumber of analysts at each rating.
REVB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
REVB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.88 | −$0.94 | −$0.82 | −$7.08 | +87.6% | 2 |
| Current fiscal year (2026) | −$5.18 | −$5.20 | −$5.17 | −$23.95 | +78.3% | 2 |
| Next fiscal year (2027) | −$2.89 | −$3.42 | −$2.36 | −$5.18 | +44.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
REVB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
REVB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
REVB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.81 | −$0.81 | −$0.81 | −$0.81 | −$0.88 | +9.3% | 0 up · 0 down |
| Current fiscal year (2026) | −$5.00 | −$5.00 | −$5.00 | −$5.00 | −$5.18 | +3.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.77 | −$2.77 | −$2.77 | −$2.77 | −$2.89 | +4.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
REVB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; REVB beat in 5 of 12.
What analysts expect from REVB
1 analysts cover Revelation Biosciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.75, 3,559.8% above the latest close of $0.48. Analysts expect earnings of −$5.18 per share for 2026, +78.3% from a year earlier. For 2027 the average estimate is −$2.89 per share. Revelation Biosciences beat the EPS estimate in 5 of the last 12 quarters.
Related: REVB income statement, REVB key metrics, REVB chart. See the REVB stock overview for the latest quote and news.
REVB forecast FAQ
What is Revelation Biosciences's price target?
The average analyst price target for Revelation Biosciences is $17.75, 3,559.8% above the latest close of $0.48.
Is Revelation Biosciences a buy, hold or sell?
Of 1 analysts covering Revelation Biosciences, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Revelation Biosciences's EPS forecast?
Analysts forecast −$5.18 per share for 2026 (range −$5.20 to −$5.17); for 2027 the estimate is −$2.89.
When does Revelation Biosciences report earnings?
Revelation Biosciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.88.
Does Revelation Biosciences usually beat earnings estimates?
Revelation Biosciences reported EPS at or above the analyst estimate in 5 of the last 12 quarters.